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ABSTRACT  
Background: It has been reported that noni has multiple health benefits for over 2000 years. In 
this study, the cancer preventive effects of Tahitian noni® juice (TNJ) at the initiation stage on 
DMBA-induced mammary tumorigenesis in female SD rats was investigated. 
 
Objective: We took advantage of the DMBA-induced mammary carcinogenic model to study 
the preventive effects of TNJ at the initiation stage of mammary carcinogenesis in female SD 
rats by using clinical observation, pathological examination, and 
32P-postlabeling assay. 
 
Methods: One hundred and sixty female SD rats were divided into eight groups with 20 rats in 
each group. Three doses of TNJ or placebo was given to the animals at the age of 35 days until 
the end of the experiment. When the animals were 55 days old, 25 mg/kg DMBA was fed to the 
animals in the DMBA group, placebo, and TNJ groups. The 20 rats were kept at age-matched 
controls.  Palpable  tumors  were  examined  twice  a  week  after  DMBA  administration  in  each 
group by an experienced professional. The size of tumor was measured by a graduated caliper. A 
piece of tumor, vascularization area, and mammary glands in the thoracic and abdomen areas of 
each  rat  were  dissected  respectively  and  fixed  in  10%  neutral  buffered  formalin  for  light 
microscope examination. The DMBA-DNA adduct formation in mammary tissues was detected 
by 32P-postlabeling assay. 
 
Results: The tumor latency in TNJ groups was delayed about 60-90 days when compared with 
positive controls. The number of palpable tumors per group was significantly reduced by 73%, 
72% and 80% in  3%,  5%, and 10% TNJ groups  respectively  when  compared with  positive 
controls at the end of 330 days after DMBA administration. The number of palpable tumors in 
the placebo groups was slightly reduced in the early stage, but much less than that in the TNJ 
groups. The multiplicity and malignancy of lesions were significantly reduced and the survival 
rate of animals in the TNJ groups was significantly increased compared with positive controls at Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 204 of 222 
different time points. Histological examination showed that the malignancy of lesions in TNJ 
groups did  not  show a significant  change  when  compared with  that in positive and placebo 
groups.  
 
Conclusion: In conclusion, this is the first study which indicates that TNJ possesses a cancer 
preventive effect at the initiation stage of chemical carcinogenesis induced by DMBA in female 
SD rates.   
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BACKGROUND: 
The species Morinda citrifolia L. (noni) belongs to the genus Morinda and the family Rubiaceae.  
Morinda includes about 80 species in which noni is considered the “queen” of all the species (1). 
The noni plant is an evergreen that can range from a small bush to a 30-foot tall tree. The tree 
produces  a  fragrant  white  flower,  blooming  year  round.  Noni  fruit  has  a  lumpy  texture, 
resembling a ‘hand grenade’, with  a rancid taste and smell when fully ripened. The fruit is 
covered with reddish-brown pits that contain seeds. Each seed has an attached air sac, allowing it 
to float for months in the ocean. Historians believe that noni originated in Southeast Asia, and 
then  migrated  to  colonize  new  lands  such  as  Micronesia  and  Polynesia  (2).  The  Polynesian 
culture has a rich healing heritage and knowledge about noni’s medicinal uses that have been 
handed down over many generations (3). Scientific literature about Noni is limited with only 
about 100 papers published to date. The majority of these publications are from South East Asia. 
Noni, named Ba Ji Tian in China, has been used since the Han Dynasty as a major Chinese herb 
for over 3000 years (4). Noni is the Hawaiian name for Morinda citrifolia, which is also known 
as “Indian mulberry” or “Och” in India, “Mengkudo” in Malaysia, “Nhau” in Southeast Asia, 
“painkiller bush” in the Caribbean, “Cheesfruit” in Australia, and “Nono” in Tahiti (5). Noni has 
recently received increased attention from modern herbalists, medical physicians, and high-tech 
biochemists. Scientific studies within the last few decades support the Polynesians’ claim of its 
unusual healing powers. These studies have shown that the juice made from noni fruit may 
possess  several  healing  effects  such  as  anti-bacterial,  anti-inflammatory,  analgesic,  anti-
congestive, hypotensive, and anti-cancer effects (6). Dr. Hirazumi, a researcher from Hawaii 
University, reported anti-cancer activity from the alcohol-precipitate of noni puree (noni-ppt) on 
Lewis lung cancer in C57 Bl/6 mice in 1992. The noni-ppt was shown to significantly prolong 
the life of mice up to 75% with implanted Lewis lung carcinoma compared with the control 
group.  It  was  concluded  that  the  noni-ppt  seems  to  suppress  tumor  growth  indirectly  by 
stimulating the immune system (7). Improved survival time and curative effects occurred when 
noni-ppt was combined with sub-optimal doses of the standard chemotherapeutic agents such as 
adriamycin  (Adria),  cisplatin  (CDDP),  5-fluorouracil  (5-FU),  and  vincristine  (VCR).  These 
findings suggest important clinical applications of noni-ppt as a supplemental agent in cancer 
treatment using chemotherapeutic agents. These results indicate that noni-ppt may enhance the 
therapeutic effect of anticancer drugs (8). In 1993, Hiramatsu and colleagues reported the effects 
of over 500 extracts from tropical plants on the K-Ras-NRK cells (9). Damnacanthal, isolated Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 205 of 222 
from Noni roots, is an inhibitor of Ras function. The Ras oncogene is believed to be associated 
with signal transduction function in several human cancers including lung, colon, pancreas, and 
leukemia  (10).  Hiwasa  and  coworkers  demonstrated  that  damnacanthal,  an  anthraquinone 
compound, isolated from the Noni root, had a potent inhibitory activity on tyrosine kinases such 
as: Lck, Src, Lyn, and EGF receptor (11). These compounds also blocked phosphorylation of c-
Jun, a substrate of JNKs, suggesting that JNKs are a critical target for the compounds mediating 
AP-1 activity and cell transformation (12).  
A number of major components have been identified in noni plant such as scopoletin, 
terpenoids,  anthraquinone  glycoside,  -sitosterol,  flavone  glycosides,  Alizarin,  acubin,  L. 
asperuloside, caproic acid, caprylic acid, ursolic acid, rutin, and a putative proxeronine (13-17). 
A research group led by Chi-tang Ho at Rutgers University has successfully identified several 
new flavonol glycosides, an iridoid glycoside from the Noni leaves, a trisacharide fatty acid 
ester, rutin, and an asperulosidic acid from the fruit. Two novel glycosides and a new unusual 
iridoid  named  citrifolinoside  from  Noni  fruit  have  shown  an  inhibitory  effect  on  AP-1 
transactivation, and cell transformation, in the mouse epidermal JB6 cell line (18-20). James 
Duke listed 23 different phytochemicals found in Noni as well as 5 vitamins and 3 minerals in an 
authoritative CRC handbook (21). 
Our  hypothesis  is  that  Noni  juice  possesses  a  preventive  agent(s)  that  works  at  the 
initiation stage of mammary chemical carcinogenesis.   
Breast cancer is the most common cancer and  the second leading cause of cancer death in 
U.S. women (22). The etiology of breast cancer remains unknown and a preventive means for 
breast cancer is unavailable (23). Although Tamoxifen is able to reduce the risk of recurrence in 
localized  breast  cancer,  there  is  still  no  definitive  way  to  prevent  breast  cancer  (24). 
Epidemiological  studies  indicate  that  environmental  factors  play  an  important  role  in  breast 
cancer etiology and a diet rich in fruits and vegetables is associated with a reduced breast cancer 
risk (25-26). The last several decades have witnessed an incredible increase in the values placed 
on fruits, vegetables, medicinal herbs, and other botanical products in cancer prevention and 
treatment  (27).  In  fact,  phytochemists  have  identified  hundreds  of  ‘phytochemicals’  that  are 
being evaluated for the prevention and treatment of cancer (28-29). It has been postulated that 
plant components may modify various stages of chemical carcinogenesis in different ways. They 
may  modify  carcinogen  activation  by  inhibiting  phase  I  enzyme  activities,  detoxifying 
carcinogens  by  enhancing  phase  II  enzyme  activities,  scavenging  DNA  reactive  agents,  and 
repairing  carcinogen damaged DNA by enhancing DNA repair enzymes in the initiation stage of 
carcinogenesis. They may also suppress the abnormal proliferation of early neoplastic lesions at 
the promotion stage, and inhibit certain properties of the cancer cell at the progression stage of 
carcinogenesis. They may directly act as an anti-cancer component or indirectly kill cancer cells 
as a biological response modifier; more specifically, as an immunomodulator. Ultimately they 
may act on the process of carcinogenesis at more than one stage (30). It is very difficult to 
identify the etiology of human breast cancer because of the complex interactions of extrinsic and 
intrinsic  carcinogenic  exposures  along  with  the  diverse  genetic  susceptibility  of  the  U.S. 
population (31). Thus, understanding the precise molecular mechanism of a preventive agent in 
such an intricate and complicated system, such as human breast carcinogenesis, is extremely 
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The  DMBA  induced  rat  mammary  carcinoma  model,  developed  40  years  ago  by  Dr. 
Charles  Brenton  Huggins,  has  become  the  standard  laboratory  model  of  mammary 
carcinogenesis  (32).  This  model  illustrates  basic  principles  of  initiation,  promotion,  and 
progression stages of mammary carcinogenesis (33). This is an ideal model to test the hypotheses 
relating the role of specific oncological events to mammary cancer development, as well as to 
examine the strategies for the prevention of human breast cancer (34). This model has a number 
of advantages that make it particularly attractive to the experimental oncologist. They are as 
follows: (a) tumor induction is easy and reliable, a single feeding of DMBA to 40-60 day-old 
female SD rats results in mammary tumor yields of 100% induction only a few months after 
DMBA treatment; (b) tumor induction is target specific, primarily involving mammary glands; 
(c) tumor origin is from ducts, TEB (terminal end bud) is the target site that is similar to human 
breast cancer; (d) tumors induced by DMBA are predominantly carcinomatous histopathological, 
which mimics human breast cancer; (e)  tumors  induced by DMBA are responsive to growth 
factors  and/or  hormones;  and  (f)  this  model  has  the  potential  to  examine  a  single  stage  of 
initiation,  promotion,  or  progression  in  mammary  carcinogenesis.  Therefore,  mammary 
tumorigenesis in female SD rats induced by DMBA is one of the most utilized models to study 
and  understand  the  pathogenesis  of  mammary  carcinogenesis  and  to  screen  for  effective 
preventive agents (35).  
In this study, we took the advantage of the fore mentioned attributes of the DMBA-induced 
mammary tumor model to evaluate the preventive effects of TNJ.  Specifically we looked at the 
initiation stage of mammary carcinogenesis in female SD rats using clinical observation and 
pathological examination.  
 
MATERIALS AND METHODS: 
Noni juice and placebo: The TNJ used in this study was donated by Tahitian Noni International 
Inc., which is a formulated form of Tahitian Noni puree mixed with blueberry and grape juice 
(36). The placebo was prepared by the R & D department of Tahitian Noni International Inc. by 
following the same procedure of Noni juice preparation, the only difference between Noni juice 
and placebo is the Noni puree is replaced in the placebo with cheese flavor. Three doses of 3%, 
5%,  and  10%  TNJ  and  three  doses  of  3%,  5%,  and  10%  placebo  were  freshly  prepared  in 
drinking water on a daily basis and supplied in the drinking water from the age of 35 days until 
the end of the study. 
 
Chemicals:  7,12-Dimethylbenz(a)anthrancene  (7,12-DMBA)  was  purchased  from  Sigma 
Chemical (St. Louis, MO, USA) and dissolved in DMSO. This was then diluted with corn oil to 
1% DMSO in corn oil before use. All materials and enzymes used in 
32P-postlabeling assay were 
described in a previous study (37). 
 
Animals: Weanling female Spargue–Dawley rats were purchased from Charles River 
Laboratories, Inc. (251 Ballardvale Street, Wilmington, MA, USA).  They were housed in 
stainless steel cages with sawdust bedding with four animals per cage,  standard animal 
husbandry environment of controlled lighting (lights on 06.00–20.00 h), and temperature 
(25 ± 1°C) at the animal center, University of Illinois College of Medicine at Rockford, IL, USA. Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 207 of 222 
Rat chow and tap water were provided ad libitum. The experimental protocol was approved by 
the animal ethical committee in accordance with the university guideline for the care and use of 
laboratory animals.  
 
Experimental design: One hundred and sixty, 35 day old, virgin female SD rats were divided 
into  eight  groups  with  20  animals  each.  Animals  in  the  age-matched  control  group  were 
maintained  on  the  regular  animal  chow  and  water  to  monitor  the  development  of  normal 
mammary glands and the incidence of spontaneous tumors during the period of the experiment. 
Animals in the DMBA group were positive controls to document the efficacy of the carcinogenic 
model. Three doses of 3%, 5%, and 10% placebo and three doses of 3%, 5%, and 10% TNJ 
groups were supplied in drinking water two weeks before DMBA administration until the end of 
the protocol. A single dose of 25 mg/kg DMBA was fed to all animals (except the age-matched 
control group) at the age of 55 days.  Please see the details in Scheme 1. 
 
Scheme 1. Experimental design to examine the cancer preventive effect of TNJ on mammary 
carcinogenesis induced by DMBA in female rats at the initiation stage  
    
 25 mg/kg DMBA dissolved in 1% DMSO in corn oil, p.o                      Animals were sacrificed                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                                                                                                                 
   |___|______|______|______|______|______|______|______|______|____________ ______  ______   
 -15   0          30         60        90        100       120       150       180       210       240         270         300         330   
                     
                                               Days         
   _______________________________________________________________________________   
 
 3%, 5%, and 10% of placebo or 3%, 5%, and 10% TNJ in drinking water was supplied 15 days 
before DMBA administration and continuously supplied until the end of the experiment. 
 
            Group 1   Age-matched control supplied with water only. 
            Group 2   Positive control group supplied with 25 mg/kg DMBA only. 
            Group 3   3% placebo in drinking water with 25 mg/kg DMBA. 
            Group 4   5% placebo in drinking water with 25 mg/kg DMBA. 
            Group 5   10% placebo in drinking water with 25 mg/kg DMBA. 
            Group 6   3% TNJ in drinking water with 25 mg/kg DMBA. 
            Group 7   5% TNJ in drinking water with 25 mg/kg DMBA. 
            Group 8   0% TNJ in drinking water with 25 mg/kg DMBA. 
 
Clinical  observation:  Palpable  tumors  were  examined  once  a  week,  after  DMBA 
administration, in each group by an experienced professional. Tumor size was measured by a 
graduated caliper. Any animal bearing a tumor of more than 2 cm in diameter was sacrificed to 
avoid animal suffering. The tumor size was calculated by the longest diameter (L) times the 
shortest diameter (S) in millimeter (L x S mm
2). The latency, size, and multiplicity of tumors 
were considered as  major parameters to evaluate the preventive effect of an agent during the 
tumor development. The body weight of each animal in each group was also recorded every Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 208 of 222 
week. The surviving animals and the animals without tumors in each group were also verified at 
the same time points as those animals with tumors.  
 
Histological examination: At 330 days post DMBA administration, all surviving animals were 
sacrificed in CO2 chamber, followed by a midline incision from the pubis to the sumaxillary 
area. The skin was dissected to expose six pairs of mammary glands. Any gross modification of 
the mammary fat pad by vascularization or any tumors present were removed. A piece of tumor, 
vascularization area, and mammary glands in the thoracic and abdomen areas of each rat was 
dissected  respectively  and  fixed  in  10%  neutral  buffered  formalin  for  light  microscope 
examination. The paraffin blocks were serially sectioned at a thickness of 5  (38). Consecutive 
sections were stained with H & E and examined under the light microscope by experienced 
pathologists. The pathologists were blinded by code numbers.  
The earliest pathogenic changes in mammary gland tissues were epithelial hypertrophy and 
hyperplasia, called “intraductal proliferation” in the terminal end bud (TEB). TEB is the site of 
origin of most rat and human mammary adenocarcinomas. These pathogenic changes were easily 
distinguished from the gland’s normal intraductal structures by the presence of a multi-layered 
epithelium. The “initiated” intraductal proliferation remained unchanged during the entire post-
carcinogen  observation  period.  The  “promoted”  intraductal  proliferation  could  progress  to 
“carcinoma  in-situ”  and  then  to  “invasive  adenocarcinoma”.  The  categories  of  histological 
examination  were  diagnosed  by  the  defined  stages  of  mammary  carcinogenesis.  TNJ  might 
suppress tumor initiation and blunt the progression of initiated cells to full malignancy (39). 
 
DMBA-DNA  adduct  detection  in  mammary  gland  tissue:  Twelve  female  SD  rats  were 
divided into three groups consisting of 4 each (age 35 days): Control, 10% placebo, and 10% 
TNJ. Animals were pretreated with 10% placebo or 10% TNJ in drinking water for two weeks. 
Control animals were maintained on a regular diet and water. One dose of 25 mg/kg DMBA was 
fed to the animals when they were age 55 days old. Animals were sacrificed at the 24th hour post 
DMBA administration and the mammary gland tissues were collected for the DMBA-induced 
DNA adducts analysis. Mammary gland DNA was isolated by a classical phenol-chloroform 
extraction  and  ethanol  precipitation  method  (40).  The  DMBA-DNA  adduct  formation  was 
detected by nuclear P1 procedure using a 
32P-postlabeling assay. The relative DNA adduct levels 
in the mammary gland tissue were calculated (41).   
 
Statistical analysis and data interpretation: In order to assess the preventive effect of TNJ on 
mammary tumor models induced by DMBA, tumor incidence, latency, size, multiplicity, as well 
as  body  weight  were  evaluated  at  different  time  points  in  different  groups  after  DMBA 
administration. The differences between these parameters in various groups were analyzed using 
Student’s T test (42).  
 
RESULTS: 
Latency of tumor and tumor incidence: The earliest tumors appeared and were detected at day 
60 after DMBA administration in the positive control group, while the first tumors to be detected Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 209 of 222 
were  at  day  90  in  3%  TNJ  group,  120  days  in  5%  and  10%  TNJ  groups  after  DMBA 
administration (Figure 1).  
 
 
 
Figure 1. Multi-tumors (six) detected in a female SD rat at 120 days after DMBA administration 
in positive control. Tumors are circled by a dotted line and numbered 1 through 6. Most tumors 
are located in the chest area.     
 
These findings indicated that the latency of tumor appearance in 3% TNJ group was delayed by 
30 days, and 60 days in 5% and 10% TNJ groups. Thus, the tumorigenesis was significantly 
suppressed by TNJ at the initiation stage of carcinogenesis. The earliest tumor detected in the 
three placebo groups was on day 120, similar to the three groups treated with TNJ.                       
  The number of palpable tumors rapidly increased  in the positive control and three doses 
of placebo, although the tumor number in placebo groups showed slightly less than positive 
controls. The number of accumulated palpable tumors was significantly decreased in all three 
doses of TNJ in a dose dependent manner. In the 3% TNJ group, the number of tumors increased 
slowly with time, while the number of tumor in 5% and 10% TNJ groups were only slightly 
increased  at  210  days  to  270  days  after  DMBA  administration  respectively.  The  number  of 
tumors in 10% TNJ at the end of 330 days was lowest compared with 3% and 5% TNJ groups. 
Although the number of accumulated tumors in the placebo groups was slightly lower than the 
positive  control  group,  the  number  of  tumors  at  each  time  point  was  much  higher  than  the 
various doses of TNJ groups. The accumulated tumor curves between Noni and placebo groups 
were completely separated by the end of 330 days. The number of tumors per group in the 
placebo group almost approached the positive control, whereas the accumulated tumors in TNJ 
groups were significantly lower than the positive control. Therefore, TNJ showed a significant 
preventing effect on DMBA induced mammary carcinogenesis at the initiation stage, in a dose 
dependent manor. A spontaneous tumor was also observed in control group at day 270 (Figure 
2).           
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Figure 2. The palpable tumors were detected in each group at different time points and the 
number of tumor detected in each group was increased with time after DMBA administration. A 
spontaneous tumor was also detected in a control animal. 
 
Table 1A. Mean number of tumors at 210, 270, or 330 days by group 
 
 
Days  Mean 
Control 
Mean 
DMBA 
Mean 
3% Placebo 
Mean 
5% Placebo 
Mean  
10% Placebo 
Mean 
3% Noni 
Mean 
5% Noni 
Mean 
10% Noni 
210  0.00  3.00  1.60  1.00  1.00  0.60  0.10  0.10 
270  0.00  4.00  1.70  1.90  2.10  0.80  0.90  0.10 
330  0.05  4.00  2.80  2.90  3.60  1.10  1.10  0.80 
 
 
 
Table 1B: Group Comparisons: Non-parametric test of differences in mean number of tumors at 
210, 270, or 330 days. 
 
Comparison between groups 
210 days  270 days  330 days 
p value  p value  p value 
Control vs DMBA  0.000  0.000  0.000 
 
3% placebo+DMBA vs 3% NJ+DMBA  0.040  0.059  0.004 
5% placebo+DMBA vs 5% NJ+DMBA  0.000  0.003  0.001 
10% placebo+DMBA vs 10% NJ+DMBA  0.002  0.000  0.000 
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DMBA vs 3% NJ  0.000  0.000  0.000 
DMBA vs 5% NJ  0.000  0.000  0.000 
DMBA vs 10% NJ  0.000  0.000  0.000 
 
Notes: All comparisons show differences in the mean number of tumors at p < 0.01. Because 
variances were not equal between groups and n was 20 per group a nonparametric test, Mann-
Whitney test, was used to compare group differences (50). 
 
Table 2A.   Distribution of the malignancy of tumor based on the histopathological report 
 
Table 2B. Group Comparisons: Non parametric Test of Differences in category of 
histopathological lesions (%) of percentage of atypical hyperplasia, benign, and malignant tumor 
 
Comparisons between groups  Atypical hyperplasia   Benign tumors   Malignant tumors  
p value  p value  p value 
Control  vs DMBA  > 0.05  < 0.05  < 0.05 
3% placebo+ DNBA  vs 3% NJ+DMBA  < 0.05  > 0.05  > 0.05 
5% placebo+ DMBA  vs 5% NJ+DMBA  < 0.05  > 0.05  > 0.05 
10% placebo+ DMBA  vs 10% NJ+DMBA  < 0.05  > 0.05  > 0.05 
DMBA vs 3% NJ  < 0.05  > 0.05  > 0.05 
DMBA vs 5% NJ  < 0.05  > 0.05  > 0.05 
DMBA vs 10% NJ  < 0.05  > 0.05  > 0.05 
 
Groups  Category of histopathological lesions (%) 
Atypical hyperplasia  Benign tumors  Malignant tumors 
Control  0.0  100.0  0.0 
DMBA  0.0  7.3  92.7 
3% placebo+DNBA  3.5  7.2  89.3 
5% placebo+DMBA  3.6  6.4  90.0 
10% placebo+DMBA  3.4  7.9  88.7 
3% NJ+DMBA  15.1  9.1  75.8 
5% NJ+DMBA  13.8  10.0  76.2 
10% NJ+DMBA  14.2  9.6  76.2 
 
The differences between groups in Table 2 (placebo versus NJ) and other comparisons between 
groups were done using a test for differences between rates described by Dever (51). This test 
calculates the 95% confidence interval difference in the percent with tumors to assess whether a 
statistically  significant  difference  in  the  percent  with  three  categori es  of  tumors  (Atypical 
hyperplasia, benign, or malignant) is occurring. These comparisons are made between groups of 
rats with NJ supplementation at three concentrations (3%, 5% or 10%) in comparison to placebo 
groups at identical concentrations. The results of these comparisons are shown in Table 2. The 
statistical analysis indicated: 1. Mammary gland tumors were significantly induced by DMBA 
when compared with the control group, which demonstrated the tumor induction by DMBA in 
female SD rats was successful; 2. The corresponding dose-dependent data analysis of placebo 
and NJ indicated that they were significantly different in atypical hyperplasia, but no on benign 
and malignant tumor; 3. Data analysis between DMBA and three doses of NJ showed there was a 
significant difference on atypical hyperplasia category, but not on benign or malignant tumor. Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 212 of 222 
Our data indicated that NJ may prevent mammary tumorigenesis at the initiation stage. Less 
significance was observed on benign and malignant tumor categories although the absolute data 
of malignancy of tumor looks lower in three doses of NJ than corresponding placebo. It indicates 
that early prevention is the key to stop mammary tumorigenesis and NJ may be not able to revise 
the malignancy of tumor if NJ was given after tumor induction. NJ may be able to reduce the 
size of tumor, but not change the characterization of tumor. 
 
Multiplicity: The tumor multiplicity was calculated based on the number of tumors detected, 
divided  by  number  of  animals  in  each  group  at  day  210,  270,  and  330  post  DMBA 
administration. The data were shown in Table 3. The multiplicity of tumors in each of the TNJ 
groups was much lower than any of the positive control or placebo groups.    
 
Table 3.   Multiplicity of tumor 
              _____________________________________________________________ 
        ------------------------------------------------------------------------------   
  Groups                     210 days               270 days          330 days 
            ------------------------------------------------------------------------------- 
  Control                             0                             0                    0.05 
DMBA                            3                             3.8                 4.0 
3% placebo                      1.6                          1.7                  2.8 
5% placebo                      1.0                          1.9                  2.9 
10% placebo                    1.0                          2.1                  3.6 
3% Noni                            0.6                         0.8                  1.1 
5% Noni                            0.1                         0.9                  1.1 
10% Noni                          0.1                         0.1                  0.8
  ________________________________________________________ 
 
Malignancy: The malignancy of tumors was examined by histological examination of each of 
the  12  pairs  of  mammary  gland  tissues  per  rat  under  the  light  microscope  by  experienced 
pathologists.  The result was shown in Table 2A and Figure 3. The malignancy of tumors in TNJ 
group was shifted to typical hyperplasia and benign lesions compared with the malignancy of 
tumors in the positive control and placebo groups. 
   
 Table 2A. Distribution of the malignancy of tumor based on the histopathological report 
 
 
 
 
 
 
 
 
 
 
Groups  Category of histopathological lesions (%) 
Typical hyperplasia  Begnin tumors  Malignant tumors 
Control  0.0  100.0  0.0 
DMBA  0.0  7.3  92.7 
3% placebo+DNBA  3.5  7.2  89.3 
5% placebo+DMBA  3.6  6.4  90.0 
10% placebo+DMBA  3.4  7.9  88.7 
3% TNJ+DMBA  15.1  9.1  75.8 
5% TNJ+DMBA  13.8  10.0  76.2 
10% TNJ+DMBA  14.2  9.6  76.2 Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 213 of 222 
 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.   Histopathological examination of the mammary gland. a. Normal mammary tissue showing 
fibrous and fatty stroma containing benign ducts and lobules. b. Mild hyperplasia of ductal epithelium is noted. 
c. Ducts lined by benign epithelium are distorted in shape in this example of fibroadenoma- like change. d. Ductular 
proliferation of monotumous cells with nuclear enlargement and atypia characterizes this adenocarcinoma. 
 
Survival animals per group at different time point after DMBA administration: The number 
of animals which survived in each group overtime was recorded and the data were shown in 
Figure 4. The age-matched controls and animals in TNJ groups showed a higher survival rate 
than the positive control and placebo groups.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. The surviving rats in the age-matched control and TNJ groups were higher survival 
rates  than positive control and placebo groups. 
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Growth curve: The trends of growth curves in different groups were similar, except for the 
positive controls. The animals in the positive control showed body weight lost after 270 days 
post DMBA administration due to bearing a larger amount of bigtumors (Figure 5).       
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Figure 5. The growth curve in each group showed a similar trend except animals in the positive 
control group had decreased body weight at day 270 (post DMBA administration) due to their 
tumor burden. 
 
DNA adduct analysis: A typical DMBA-DNA adduct pattern was observed in the mammary 
gland tissues in female SD rats (Figure 6). The DMBA-DNA adduct level was significantly 
decreased after drinking 10% TNJ for two week before DMBA administration. There was no 
detectable DNA adducts observed in mammary gland tissues of control animals (Table 4).  
 
 
         
 
 
 
 
 
 
   
 
 
 
 
Figure 6. A typical autoradiography map of DMBA-DNA adduct detected in the mammary gland tissues of female 
SD rats by 
32Postlabeling assay at 24th hour post DMBA (25 mg/kg, p.o administration (B). The x-ray film was 
exposed at -80
o C for 6 hours. There was no DNA adducts detected in control mammary gland tissues. “is”=internal 
standard. The spots of the DMBA DNA adducts were labeled as spots 1, 2, 3, 4, 5, 6, 7, 8, and 9.     
 Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 215 of 222 
Table 4. TNJ reduced DMBA-DNA adducts level in mammary gland tissues 
   
Groups  DMBA-DNA adduct level x 10
6 
Mean ± SD  Reduction (%)  P value 
DMBA  3.55 ± 0.94     
10% placebo + DMBA  3.28 ± 0.94  7.6  > 0.05 
10%TNJ + DMBA  1.30 ± 0.82  63.4  < 0.01 
 
 
DISCUSSION:  
Several interesting findings were discovered in this study. Mammary tumors were successfully 
induced by feeding one dose of 25 mg/kg DMBA (at age 55 days) in female SD rats.  The 
number of palpable tumors  rapidly increased  with  time in  the positive control  group, and  a 
solitary spontaneous tumor was also observed in one of the 20 age-matched control animals (at 
day  325).  TNJ  continuously  suppressed  the  tumor  incidence  and  tumor  growth  in  a  dose 
dependent  manner  until  day  270  (after  DMBA  administration).  While  placebo  suppressed 
palpable tumor incidence was only at the early stage of tumorigenesis, the number of palpable 
tumors rapidly increased with time after day 210 (post DMBA administration). The number of 
tumors  in  the  placebo  groups  approached  the  positive  control  group  by  the  330  days  (post 
DMBA  administration).  Therefore,  the  lowest  number  of  tumors  observed  in  different  TNJ 
groups  indicated  that  TNJ  indeed  had  a  significant  preventive  effect  on  DMBA-induced 
mammary carcinogenesis in female SD rats (p < 0.01). 
The latency of tumors in positive control animals was the shortest compared with that in 
the placebo and TNJ groups. The latency of tumors was significantly prolonged by TNJ, while 
placebo groups had a relatively longer latency compared with that in positive control group. Due 
to the anti-oxidant property of the placebo, which consisted of grape and blue berry juice, a mild 
preventive  effect  at  the  earlier  stage  of  tumor  development  was  anticipated.  The  number  of 
tumors in the placebo groups rapidly increased after day 210 (post DMBA administration) and 
approached  the  positive  control  at  day  330  (post  DMBA  administration).  Therefore,  tumor 
latency was delayed by TNJ and the number of tumors was also reduced by TNJ in DMBA-
induced  mammary  carcinogenesis  when  TNJ  was  supplied  to  the  animal  two  weeks  before 
DMBA administration. The multiplicity of tumors in the TNJ groups was significantly low (p < 
0.01), some of the SD rats in the positive control group bore more than six tumors, and some of 
tumors showed abundant blood supply (angiogenesis) (Figure 7). This was never observed in 
TNJ treated animals. It has been reported that TNJ possessed an anti-angiogenic agent (43). 
Palpable tumors were observed in 5% of animals in the control group, 90% of animals in the 
DMBA positive control group, 75% of animals in the 3% placebo, 80% of animals in the  5% 
placebo, and 95% of animals in the 10% placebo groups. Whereas only 65% of animals in the 
3% TNJ, 40% of animals in the 5% TNJ, and 40% of animals in the 10% TNJ group were 
observed  to  have  tumors.  In  other  words,  60%  of  the  animals  were  protected  from  DMBA Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 216 of 222 
tumorigenesis by drinking 5% or 10% TNJ in drinking water. If we group the average tumor 
number in each animal of these different groups, the animals in the 3%, 5%, and 10% TNJ 
groups have much fewer tumors. There is a 73%, 73%, and 80% reduction of tumors respectively 
compared with that in DMBA positive control animals at day 330 (after DMBA administration).  
Meanwhile, there was only a 30% reduction in the 3% placebo, 27.5% reduction in the 5% 
placebo,  and  10%  reduction  in  the  10%  placebo  groups  respectively.    Thus,  the  significant 
reduction of tumor number per animal was observed in TNJ groups (p < 0.01).  
 
 
 
 
Figure 7. A big tumor was detected in positive control group at day120 post DMBA administration. Abundant blood 
supply was clearly shown surrounding the tumor. This tumor was adenocarcinoma confirmed by histopathological 
examination. 
 
Histopathological examinations showed the neoplastic growth in the TMJ group to be shifted to 
hyperplasia and benign tumors, rather than the malignant tumors detected in the positive control 
and placebo groups. 
The growth curve in each group showed the same trend except the positive controls. The 
body weight in positive control group was decreased after 270 days post DMBA administration 
because of their tumor burden. The animals in this group were skinny, were less active, and had 
dry hair. Animals in TNJ group looked much healthier, were more energetic, highly active, and 
had shinny hair. There were no adverse effects of TNJ observed in this long-term experiment.    
This study represents the first attempt to understand the initial mechanism of the cancer 
preventive effect of TNJ. The DMBA induced DNA adducts level showed that they may be the 
most important biomarker to evaluate the cancer preventive effect of TNJ at the initiation stage 
of chemical carcinogenesis. The results indicated that the DMBA DNA adduct level in mammary 
gland tissues was significantly decreased (p < 0.01) by drinking 10% TNJ for two weeks before 
DMBA administration. This finding suggests the idea that TNJ may be an important agent that is 
responsible for the preventive effect at the initiation stage of tumorigenesis. The DNA adduct 
levels measured in the mammary gland tissue were the net result after the carcinogen activation, 
detoxification, and DNA repair. Therefore, whether TNJ inhibits the activities of the phase 1 
enzymes (cytochrome P450s), or enhances the activities of the phase 2 enzymes, and DNA repair Functional Foods in Health and Disease 2013; 3(6):203-222                                                             Page 217 of 222 
enzymes, remains to be determined in the future (43). In addition, the anti-oxidant property, anti-
inflammatory, anti-proliferative activities, and modification of immune function of TNJ may also 
contribute to the mechanisms of the preventive effect of TNJ at the initiation stage of chemical 
carcinogenesis  (44-47).  The  data  from  previous  studies  has  indicated  that  TNJ  is  able  to 
scavenge superoxide free radicals (SAR) and quench lipid peroxides (LPO) in vitro and in vivo 
(48), reduce inflammatory reaction in CCl4-induced liver injury model (49), inhibit partially 
COX-2 in vitro (50),and to prevent mammary gland tumors at the initiation stage of DMBA-
induced mammary gland tumor (51). All of this data supports our hypothesis. Most experts agree 
that the avoidance of DNA adduct formation and/or removal of carcinogen-DNA adducts is, at 
least, a possible avenue for cancer prevention since carcinogen-induced DNA adduct formation 
has long been recognized as the earliest and most critical step of chemical carcinogenesis (52). 
Previous  studies  have  demonstrated  that  aromatic  DNA  adducts  have  been  detected  in  the 
adjacent  normal  tissues  of  cancer  patients  (53).  The  level  of  these  DNA  adducts  in  cancer 
patients  is  significantly  higher  than  those  of  non-cancer  control  patients.  The  detection  of 
aromatic  adducts  in  adjacent  normal  breast  tissues  of  breast  cancer  patients  suggests  that 
exogenous carcinogens may be involved in human breast carcinogenesis (54).  
Further studies  will be  focused on the mechanisms of the mammary tumor preventive 
effect of TNJ, as well as the illustration of the major preventive components from Noni and their 
actions. Based on our data, it may be possible to develop a botanical product which is preventive 
for the people who are on the high risk of breast cancer (55). 
 
CONCLUSION: 
This is the first study indicated that TNJ possesses a cancer preventive effect at the initiation 
stage of chemical carcinogenesis induced by DMBA in female SD rates. 
The  nutrition  enhancement,  reduction  of  carcinogen  (DMBA)-induced  DNA  adduct 
formation, anti-angiogenesis, delay the patency of tumor appearance may play the key roles in 
the  preventative  mechanisms  of  TNJ  at  the  initiation  stage  of  DMBA-induced  breast 
carcinogenesis.  
 
Abbreviations: Breast cancer, DMBA, initiation stage, carcinogenesis, DNA adducts, cancer 
prevention, Morinda citrifolia (noni), Tahitian Noni juice (TNJ). 
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